Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 177

1.

[The development of real-time multispectral imaging for the diagnostics of bladder cancer].

Bolenz C, Rother J, Meessen S, Grychtol B, Majlesara A, Gharabaghi N, Günes C, Ritter M, Deliolanis N, Michel MS, Kriegmair MC.

Urologe A. 2019 Sep 17. doi: 10.1007/s00120-019-01037-3. [Epub ahead of print] Review. German.

PMID:
31531693
2.

Lithium Therapy Associated With Renal and Upper and Lower Urinary Tract Tumors: Results From a Retrospective Single-Center Analysis.

Gahr M, Wezel F, Bolenz C, Connemann BJ, Schönfeldt-Lecuona C, Muche R, Fohrer C.

J Clin Psychopharmacol. 2019 Sep/Oct;39(5):530-532. doi: 10.1097/JCP.0000000000001098. No abstract available.

PMID:
31425462
3.

Excess hepsin proteolytic activity limits oncogenic signaling and induces ER stress and autophagy in prostate cancer cells.

Willbold R, Wirth K, Martini T, Sültmann H, Bolenz C, Wittig R.

Cell Death Dis. 2019 Aug 9;10(8):601. doi: 10.1038/s41419-019-1830-8.

4.

Quality of Life and Decision Regret After Postoperative Radiation Therapy to the Prostatic Bed Region With or Without Elective Pelvic Nodal Radiation Therapy.

Link C, Honeck P, Lohr F, Bolenz C, Schaefer J, Bohrer M, Giordano FA, Wenz F, Buergy D.

Pract Radiat Oncol. 2019 Jun 27. pii: S1879-8500(19)30182-1. doi: 10.1016/j.prro.2019.06.011. [Epub ahead of print]

PMID:
31255714
5.

Postoperative elective pelvic nodal irradiation compared to prostate bed irradiation in locally advanced prostate cancer - a retrospective analysis of dose-escalated patients.

Link C, Honeck P, Makabe A, Giordano FA, Bolenz C, Schaefer J, Bohrer M, Lohr F, Wenz F, Buergy D.

Radiat Oncol. 2019 Jun 7;14(1):96. doi: 10.1186/s13014-019-1301-5.

6.

[Surgical treatment of bladder cancer: advances made in the past 50 years].

Bolenz C, Hautmann RE.

Aktuelle Urol. 2019 Aug;50(4):366-377. doi: 10.1055/a-0884-2792. Epub 2019 May 15. German.

PMID:
31091541
7.

In Reply.

Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO.

Dtsch Arztebl Int. 2019 Mar 8;116(11):192-193. doi: 10.3238/arztebl.2019.0192b. No abstract available.

8.

The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes.

Pfannstiel C, Strissel PL, Chiappinelli KB, Sikic D, Wach S, Wirtz RM, Wullweber A, Taubert H, Breyer J, Otto W, Worst T, Burger M, Wullich B, Bolenz C, Fuhrich N, Geppert CI, Weyerer V, Stoehr R, Bertz S, Keck B, Erlmeier F, Erben P, Hartmann A, Strick R, Eckstein M; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany; BRIDGE Consortium, Germany.

Cancer Immunol Res. 2019 Jun;7(6):923-938. doi: 10.1158/2326-6066.CIR-18-0758. Epub 2019 Apr 15.

PMID:
30988029
9.

Androgen Receptor mRNA Expression in Urothelial Carcinoma of the Bladder: A Retrospective Analysis of Two Independent Cohorts.

Sikic D, Wirtz RM, Wach S, Dyrskjøt L, Erben P, Bolenz C, Breyer J, Otto W, Hoadley KA, Lerner SP, Eckstein M, Hartmann A, Keck B.

Transl Oncol. 2019 Apr;12(4):661-668. doi: 10.1016/j.tranon.2019.01.005. Epub 2019 Mar 2.

10.

[Medical specialist training for urologists].

Bolenz C, Michel MS, Struck JP.

Urologe A. 2019 Feb;58(2):107-108. doi: 10.1007/s00120-019-0857-x. German. No abstract available.

PMID:
30788542
11.

Prognostic significance of BAP1 expression in high-grade upper tract urothelial carcinoma: a multi-institutional study.

Aydin AM, Singla N, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Westerman ME, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V, Krabbe LM.

World J Urol. 2019 Feb 13. doi: 10.1007/s00345-019-02678-x. [Epub ahead of print]

PMID:
30759271
12.

[Urology training in Germany: international comparison of educational concepts and satisfaction].

Cebulla A, Bolenz C, Carrion DM, Bellut L.

Urologe A. 2019 Feb;58(2):132-138. doi: 10.1007/s00120-019-0854-0. Review. German.

PMID:
30683972
13.

The Investigation of Hematuria.

Bolenz C, Schröppel B, Eisenhardt A, Schmitz-Dräger BJ, Grimm MO.

Dtsch Arztebl Int. 2018 Nov 30;115(48):801-807. doi: 10.3238/arztebl.2018.0801. Review.

14.

[Biopsy techniques in the upper urinary tract for the diagnosis of urothelial carcinoma: systematic review].

Foerster B, Shariat SF, Klein JT, Bolenz C.

Urologe A. 2019 Jan;58(1):14-21. doi: 10.1007/s00120-018-0829-6. German.

PMID:
30617531
15.

Erratum to 'Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy' [Urologic Oncology: Seminars and Original Investigations 36/12 (2018) 505-534].

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2019 Mar;37(3):227. doi: 10.1016/j.urolonc.2018.12.019. Epub 2018 Dec 27. No abstract available.

PMID:
30595464
16.

SWITCH II: Phase III randomized, sequential, open-label study to evaluate the efficacy and safety of sorafenib-pazopanib versus pazopanib-sorafenib in the treatment of advanced or metastatic renal cell carcinoma (AUO AN 33/11).

Retz M, Bedke J, Bögemann M, Grimm MO, Zimmermann U, Müller L, Leiber C, Teber D, Wirth M, Bolenz C, van Alphen R, De Santis M, Beeker A, Lehmann J, Indorf M, Frank M, Bokemeyer C, Gschwend JE.

Eur J Cancer. 2019 Jan;107:37-45. doi: 10.1016/j.ejca.2018.11.001. Epub 2018 Dec 7.

PMID:
30529901
17.

Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.

Eckstein M, Erben P, Kriegmair MC, Worst TS, Weiß CA, Wirtz RM, Wach S, Stoehr R, Sikic D, Geppert CI, Weyerer V, Bertz S, Breyer J, Otto W, Keck B, Burger M, Taubert H, Weichert W, Wullich B, Bolenz C, Hartmann A, Erlmeier F.

Eur J Cancer. 2019 Jan;106:234-243. doi: 10.1016/j.ejca.2018.11.007. Epub 2018 Dec 5.

PMID:
30528808
18.

Analysis of the prognostic relevance of sex-steroid hormonal receptor mRNA expression in muscle-invasive urothelial carcinoma of the urinary bladder.

Erben P, Sikic D, Wirtz RM, Martini T, Weis CA, Breyer J, Otto W, Keck B, Hartmann A, Bolenz C; BRIDGE Consortium e.V.

Virchows Arch. 2019 Feb;474(2):209-217. doi: 10.1007/s00428-018-2496-9. Epub 2018 Nov 27.

PMID:
30483954
19.

Predictive value of lymphangiogenesis and proliferation markers on mRNA level in urothelial carcinoma of the bladder after radical cystectomy.

Martini T, Heinkele J, Mayr R, Weis CA, Wezel F, Wahby S, Eckstein M, Schnöller T, Breyer J, Wirtz R, Ritter M, Bolenz C, Erben P.

Urol Oncol. 2018 Dec;36(12):530.e19-530.e27. doi: 10.1016/j.urolonc.2018.09.003. Epub 2018 Nov 13. Erratum in: Urol Oncol. 2019 Mar;37(3):227.

PMID:
30446441
20.

mRNA-Expression of KRT5 and KRT20 Defines Distinct Prognostic Subgroups of Muscle-Invasive Urothelial Bladder Cancer Correlating with Histological Variants.

Eckstein M, Wirtz RM, Gross-Weege M, Breyer J, Otto W, Stoehr R, Sikic D, Keck B, Eidt S, Burger M, Bolenz C, Nitschke K, Porubsky S, Hartmann A, Erben P.

Int J Mol Sci. 2018 Oct 30;19(11). pii: E3396. doi: 10.3390/ijms19113396.

21.

Cryobiopsy in the Upper Urinary Tract: Preclinical Evaluation of a Novel Device.

Klein JT, Berger F, Linzenbold W, Jäger L, Enderle MD, Bösmüller H, Mundhenk J, Schwentner C, Bolenz C.

Urology. 2019 Jan;123:273-279. doi: 10.1016/j.urology.2018.10.003. Epub 2018 Oct 9.

PMID:
30312669
22.

Cell-Free DNA and Neuromediators in Detecting Aggressive Variant Prostate Cancer.

von Hardenberg J, Worst TS, Westhoff N, Erben P, Fuxius S, Müller M, Bolenz C, Weiss C, Heinrich E.

Oncol Res Treat. 2018;41(10):627-633. doi: 10.1159/000490618. Epub 2018 Sep 10.

PMID:
30286478
23.

CDKN2A as transcriptomic marker for muscle-invasive bladder cancer risk stratification and therapy decision-making.

Worst TS, Weis CA, Stöhr R, Bertz S, Eckstein M, Otto W, Breyer J, Hartmann A, Bolenz C, Wirtz RM, Erben P.

Sci Rep. 2018 Sep 26;8(1):14383. doi: 10.1038/s41598-018-32569-x.

24.

Declining Use of Orthotopic Reconstruction for Bladder Cancer.

Hautmann R, Bolenz C.

Ann Surg Oncol. 2018 Nov;25(12):3421-3422. doi: 10.1245/s10434-018-6570-y. Epub 2018 Jul 18. No abstract available.

PMID:
30022273
25.

Subclassification, survival prediction and drug target analyses of chemotherapy-naïve muscle-invasive bladder cancer with a molecular screening.

Rinaldetti S, Rempel E, Worst TS, Eckstein M, Steidler A, Weiss CA, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 May 25;9(40):25935-25945. doi: 10.18632/oncotarget.25407. eCollection 2018 May 25.

26.

Multi-institutional evaluation of the prognostic significance of EZH2 expression in high-grade upper tract urothelial carcinoma.

Singla N, Krabbe LM, Aydin AM, Panwar V, Woldu SL, Freifeld Y, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Bagrodia A, Kapur P, Margulis V.

Urol Oncol. 2018 Jul;36(7):343.e1-343.e8. doi: 10.1016/j.urolonc.2018.04.004. Epub 2018 May 7.

PMID:
29748098
27.

A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomy.

Eckstein M, Wirtz RM, Pfannstil C, Wach S, Stoehr R, Breyer J, Erlmeier F, Günes C, Nitschke K, Weichert W, Otto W, Keck B, Eidt S, Burger M, Taubert H, Wullich B, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2018 Feb 19;9(19):15001-15014. doi: 10.18632/oncotarget.24531. eCollection 2018 Mar 13.

28.

Implications of TERT promoter mutations and telomerase activity in urothelial carcinogenesis.

Günes C, Wezel F, Southgate J, Bolenz C.

Nat Rev Urol. 2018 Jun;15(6):386-393. doi: 10.1038/s41585-018-0001-5. Review.

PMID:
29599449
29.

The concentration of console surgeons: prospective evaluation of the loss of attention in robotic-assisted procedures.

Martinschek A, Welzel G, Ritter M, Heinrich E, Bolenz C, Trojan L.

J Robot Surg. 2018 Dec;12(4):673-678. doi: 10.1007/s11701-018-0800-y. Epub 2018 Mar 17.

PMID:
29550992
30.

Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer.

Mayr R, Gierth M, Zeman F, Reiffen M, Seeger P, Wezel F, Pycha A, Comploj E, Bonatti M, Ritter M, van Rhijn BWG, Burger M, Bolenz C, Fritsche HM, Martini T.

J Cachexia Sarcopenia Muscle. 2018 Jun;9(3):505-513. doi: 10.1002/jcsm.12279. Epub 2018 Feb 25.

31.

Prognostic Value of Molecular Breast Cancer Subtypes based on Her2, ESR1, PGR and Ki67 mRNA-Expression in Muscle Invasive Bladder Cancer.

Kriegmair MC, Wirtz RM, Worst TS, Breyer J, Ritter M, Keck B, Boehmer C, Otto W, Eckstein M, Weis CA, Hartmann A, Bolenz C, Erben P.

Transl Oncol. 2018 Apr;11(2):467-476. doi: 10.1016/j.tranon.2018.02.001. Epub 2018 Feb 23.

32.

Decreased Invasion of Urothelial Carcinoma of the Bladder by Inhibition of Matrix-Metalloproteinase 7.

Bolenz C, Knauf D, John A, Erben P, Steidler A, Schneider SW, Günes C, Gorzelanny C.

Bladder Cancer. 2018 Jan 20;4(1):67-75. doi: 10.3233/BLC-170124.

33.

Quality of life after low-dose rate-brachytherapy for prostate carcinoma - long-term results and literature review on QLQ-C30 and QLQ-PR25 results in published brachytherapy series.

Buergy D, Schneiberg V, Schaefer J, Welzel G, Trojan L, Bolenz C, Wenz F.

Health Qual Life Outcomes. 2018 Jan 22;16(1):21. doi: 10.1186/s12955-018-0844-8. Review.

34.

Websites on Bladder Cancer: an Appropriate Source of Patient Information?

Salem J, Paffenholz P, Bolenz C, von Brandenstein M, Cebulla A, Haferkamp A, Kuru T, Lee CT, Pfister D, Tsaur I, Borgmann H, Heidenreich A.

J Cancer Educ. 2019 Apr;34(2):381-387. doi: 10.1007/s13187-017-1316-2.

PMID:
29313299
35.

Wide-field autofluorescence-guided TUR-B for the detection of bladder cancer: a pilot study.

Kriegmair MC, Honeck P, Theuring M, Bolenz C, Ritter M.

World J Urol. 2018 May;36(5):745-751. doi: 10.1007/s00345-017-2147-9. Epub 2017 Dec 6.

PMID:
29214354
36.

Prospective Evaluation of Neuromediator Dynamics in Castration-Resistant Prostate Cancer Patients During Docetaxel.

VON Hardenberg J, Schwartz M, Werner T, Fuxius S, Müller M, Frangenheim T, Bolenz C, Weiss C, Heinrich E.

Anticancer Res. 2017 Sep;37(9):5117-5124.

PMID:
28870943
37.

Role of the Coagulation System in Genitourinary Cancers: Review.

John A, Gorzelanny C, Bauer AT, Schneider SW, Bolenz C.

Clin Genitourin Cancer. 2017 Jul 26. pii: S1558-7673(17)30210-0. doi: 10.1016/j.clgc.2017.07.013. [Epub ahead of print] Review.

PMID:
28822718
38.

Prospective, Controlled Study of Invasiveness and Post-Aggression Metabolism in Patients Undergoing Robotic-Assisted Radical Prostatectomy.

Martinschek A, Stumm L, Ritter M, Heinrich E, Bolenz C, Trojan L.

Urol Int. 2017;99(2):201-206. doi: 10.1159/000478027. Epub 2017 Jul 29.

39.

[Role of the human ErbB family receptors in urothelial carcinoma of the bladder: mRNA expression status and prognostic relevance].

Erben P, Wezel F, Wirtz R, Martini T, Stein D, Weis CA, Hartmann A, Bolenz C.

Aktuelle Urol. 2017 Aug;48(4):356-362. doi: 10.1055/s-0043-110403. Epub 2017 Jul 27. German.

PMID:
28750448
40.

[Modern endoscopic imaging tools for urothelial carcinoma of the urinary bladder].

Kriegmair MC, Ritter M, Michel MS, Bolenz C.

Aktuelle Urol. 2017 Aug;48(4):296-305. doi: 10.1055/s-0043-109820. Epub 2017 Jul 27. German.

PMID:
28750446
41.

Oncologic Response and Hospitalization Rate of Patients Receiving Cabazitaxel in the Fourth-Line and Beyond in Castration-Resistant Prostate Cancer: Analysis of a Retrospective Cohort and a Structured Literature Review.

von Hardenberg J, Schwartz M, Werner T, Fuxius S, Strauss A, Worst TS, Nuhn P, Bolenz C, Heinrich E.

Urol Int. 2017;99(4):414-421. doi: 10.1159/000477943. Epub 2017 Jul 13. Review.

PMID:
28700990
42.

Prognostic Value of PD-1 and PD-L1 Expression in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Heitplatz B, Preuss S, Hutchinson RC, Woldu SL, Singla N, Boegemann M, Wood CG, Karam JA, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Haitel A, Rapoport LM, Glybochko PV, Roscigno M, Bolenz C, Bensalah K, Sagalowsky AI, Shariat SF, Lotan Y, Xylinas E, Margulis V.

J Urol. 2017 Dec;198(6):1253-1262. doi: 10.1016/j.juro.2017.06.086. Epub 2017 Jun 28.

PMID:
28668287
43.

[Microscopic hematuria : Reasonable and risk-adapted diagnostic evaluation].

Löbig N, Wezel F, Martini T, Schröppel B, Bolenz C.

Urologe A. 2017 Sep;56(9):1139-1146. doi: 10.1007/s00120-017-0432-2. Review. German.

PMID:
28643107
44.

Effect of Hospital and Surgeon Case Volume on Perioperative Quality of Care and Short-term Outcomes After Radical Cystectomy for Muscle-invasive Bladder Cancer: Results From a European Tertiary Care Center Cohort.

Vetterlein MW, Meyer CP, Leyh-Bannurah SR, Mayr R, Gierth M, Fritsche HM, Burger M, Keck B, Wullich B, Martini T, Bolenz C, Pycha A, Hanske J, Roghmann F, Noldus J, Bastian PJ, Gilfrich C, May M, Rink M, Chun FK, Dahlem R, Fisch M, Aziz A; PROMETRICS 2011 study group.

Clin Genitourin Cancer. 2017 Oct;15(5):e809-e817. doi: 10.1016/j.clgc.2017.04.021. Epub 2017 Apr 26.

PMID:
28550955
45.

FOXM1 predicts overall and disease specific survival in muscle-invasive urothelial carcinoma and presents a differential expression between bladder cancer subtypes.

Rinaldetti S, Wirtz RM, Worst TS, Eckstein M, Weiss CA, Breyer J, Otto W, Bolenz C, Hartmann A, Erben P.

Oncotarget. 2017 Jul 18;8(29):47595-47606. doi: 10.18632/oncotarget.17394.

46.

[When should the primary tumor of metastatic bladder or prostate cancer be treated using a nonsurgical regimen?]

Bottke D, Bolenz C, Ott S, Cebulla A, Wiegel T.

Urologe A. 2017 May;56(5):579-584. doi: 10.1007/s00120-017-0356-x. Review. German.

PMID:
28349190
47.

Digital Mapping of the Urinary Bladder: Potential for Standardized Cystoscopy Reports.

Kriegmair MC, Bergen T, Ritter M, Mandel P, Michel MS, Wittenberg T, Bolenz C.

Urology. 2017 Jun;104:235-241. doi: 10.1016/j.urology.2017.02.019. Epub 2017 Feb 16.

PMID:
28214573
48.

Expression of the p53 Inhibitors MDM2 and MDM4 as Outcome Predictor in Muscle-invasive Bladder Cancer.

Kriegmair MC, Balk M, Wirtz R, Steidler A, Weis CA, Breyer J, Hartmann A, Bolenz C, Erben P.

Anticancer Res. 2016 Oct;36(10):5205-5213.

PMID:
27798881
49.

The Use of Neoadjuvant Chemotherapy in Patients With Urothelial Carcinoma of the Bladder: Current Practice Among Clinicians.

Martini T, Gilfrich C, Mayr R, Burger M, Pycha A, Aziz A, Gierth M, Stief CG, Müller SC, Wagenlehner F, Roigas J, Hakenberg OW, Roghmann F, Nuhn P, Wirth M, Novotny V, Hadaschik B, Grimm MO, Schramek P, Haferkamp A, Colleselli D, Kloss B, Herrmann E, Fisch M, May M, Bolenz C.

Clin Genitourin Cancer. 2017 Jun;15(3):356-362. doi: 10.1016/j.clgc.2016.09.003. Epub 2016 Sep 19.

PMID:
27765613
50.

Postoperative Nomogram for Relapse-Free Survival in Patients with High Grade Upper Tract Urothelial Carcinoma.

Krabbe LM, Eminaga O, Shariat SF, Hutchinson RC, Lotan Y, Sagalowsky AI, Raman JD, Wood CG, Weizer AZ, Roscigno M, Montorsi F, Bolenz C, Novara G, Kikuchi E, Fajkovic H, Rapoport LM, Glybochko PV, Zigeuner R, Remzi M, Bensalah K, Kassouf W, Margulis V.

J Urol. 2017 Mar;197(3 Pt 1):580-589. doi: 10.1016/j.juro.2016.09.078. Epub 2016 Sep 23.

PMID:
27670916

Supplemental Content

Loading ...
Support Center